Why the study?
Does Killip class III predict mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention?
Does Killip class III predict mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention?
Killip class III remains a strong independent predictor of short- and long-term mortality in STEMI patients even in the era of primary PCI.
Killip III supports risk stratification in contemporary STEMI; leaves open whether it should guide therapy after primary PCI.
Killip III remains strongly and independently predictive of 30-day and 1-yr mortality in ST-segment elevation myocardial infarction patients even undergoing primary percutaneous coronary intervention.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: